PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

NCT04506281 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma, Intrahepatic

Interventions

DRUG: neoadjuvant treatment

Sponsor

Shanghai Zhongshan Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]